AI Can Predict Risk of Serious Heart Disease From Mammograms

Why It Matters

The approach leverages an existing, widely used cancer‑screening platform to uncover hidden cardiovascular risk in women, potentially reducing mortality through earlier intervention. It offers clinicians a scalable method to identify high‑risk patients without additional imaging infrastructure.

Key Takeaways

• AI analyzes mammograms for arterial calcium
• Study of 123,762 women shows risk escalation
• Mild calcification raises heart disease risk ~30%
• Moderate calcification increases risk over 70%
• Severe calcification triples risk, independent of other factors

Pulse Analysis

Heart disease remains the leading cause of death among women, yet many go undiagnosed because traditional risk assessments often miss early signs. Mammography, with participation rates exceeding 60% in eligible age groups, presents a unique touchpoint where AI can extract vascular information without extra radiation or cost. By quantifying breast arterial calcification, the technology transforms a cancer‑screening exam into a dual‑purpose diagnostic, aligning preventive cardiology with established women's health workflows.

The Emory‑led investigation, the largest of its kind, applied deep‑learning algorithms to over 120,000 mammograms, categorizing calcium deposits into mild, moderate, and severe tiers. Statistical analysis demonstrated a clear dose‑response relationship: women with any detectable calcification faced markedly higher odds of myocardial infarction, stroke, or cardiovascular death, even after controlling for diabetes, smoking, and cholesterol. Importantly, the signal persisted in younger cohorts traditionally deemed low‑risk, highlighting a gap in current screening paradigms that AI can fill.

Policymakers and health systems can capitalize on these insights by embedding the AI tool into existing imaging pipelines, creating automated alerts for clinicians and patients. Such integration could trigger follow‑up lipid panels, lifestyle counseling, or pharmacologic therapy, ultimately shifting the preventive care model toward earlier, data‑driven interventions. Ongoing clinical trials will test implementation pathways, reimbursement structures, and patient outcomes, paving the way for a paradigm where a single mammogram informs both oncologic and cardiovascular health strategies.